At 6months , the mean gains in BCVA were +18.1 letters ( p < 0.0001 ; 95 % CI , +12.8 to +22.6 ) in the ranibizumab group and +15.6 letters ( p < 0.0001 ; 95 % CI +12.0 to +20.5 ) in the bevacizumab group .